NEW YORK (GenomeWeb) – Shares of Foundation Medicine and Enzo Biochem each rose around 30 percent month over month in March, leading the GenomeWeb Index to a gain of around 2 percent.

The GW Index, which includes 26 firms in the omics tools and molecular diagnostics industries, outperformed the Dow Jones Industrial Average, which was down nearly 1 percent; the Nasdaq Composite, which was up a little more than 1 percent; and the Nasdaq Biotech Index, which finished March down 1 percent. Overall, 18 of the 26 stocks tracked in the GW Index made positive gains in the month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.